Novartis and Servier reach agreement on novel Major Depression drug

[APG]

Novartis And Servier Reach Agreement On Novel Major Depression Drug

Basel, Switzerland, March 29, 2006 - Novartis and Servier announced
today the signing of a licensing agreement for agomelatine, a Phase
III investigational drug for the treatment of major depressive
disorder, a condition estimated to affect one in ten adults in the US
alone.

Under development as a once-daily treatment, agomelatine is a novel
melatonergic antidepressant that acts as an agonist at MT1 and MT2
receptors with additional 5-HT2c antagonist properties. Due to its
unique receptor profile, agomelatine represents a potential innovation
for the pharmacological treatment of depression.

More:
http://anxpangazette.blog-city.com/

http://anxpangazette.blog-city.com/novartis_and_servier_reach_agreement_on_novel_major_depressi.htm

[DR AMOR]

Sounds promising. It seems like a melatonin precursor of some kind.

[Don W. McCollough]

Post by APG
Novartis And Servier Reach Agreement On Novel Major Depression Drug

Good. The more ammunition the better. Just hope its safe.

Post by APG
Basel, Switzerland, March 29, 2006 - Novartis and Servier announced
today the signing of a licensing agreement for agomelatine, a Phase
III investigational drug for the treatment of major depressive
disorder, a condition estimated to affect one in ten adults in the US
alone.
Under development as a once-daily treatment, agomelatine is a novel
melatonergic antidepressant that acts as an agonist at MT1 and MT2
receptors with additional 5-HT2c antagonist properties. Due to its
unique receptor profile, agomelatine represents a potential innovation
for the pharmacological treatment of depression.
http://anxpangazette.blog-city.com/
http://anxpangazette.blog-city.com/novartis_and_servier_reach_agreement_on_novel_major_depressi.htm